Telormedix appoints new chairman

Nicholas Rogerson has taken the role

Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.

Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.

Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.

You may also like

Manufacturing

BD and Suttons Creek collaborate to streamline combination product development for pharma and biotech

The new strategic collaboration will help pharmaceutical and biotech companies reduce development risk and regulatory complexity across drug-device combination products, including biologics and GLP-1 therapies
Regulatory

FDA grants Orphan Drug Designation to pegrizeprument for prevention of heart transplant rejection

The FDA has granted Orphan Drug Designation to pegrizeprument (VEL-101), a novel monoclonal antibody fragment licensed to Veloxis Pharmaceuticals, for the prevention of heart allograft rejection, following a similar designation granted for liver transplant rejection in January 2026
Manufacturing

Cipla receives FDA approval for first AB-rated generic of Ventolin HFA in $1.5bn US albuterol market

Indian pharmaceutical company Cipla has secured final FDA approval for its Albuterol Sulfate Inhalation Aerosol, becoming the first AB-rated generic therapeutic equivalent of GlaxoSmithKline's Ventolin HFA
Manufacturing

Japanese pharma companies shifting to earlier CDMO outsourcing as peptide complexity increases

Neuland Laboratories has reported a notable shift in Japanese pharmaceutical outsourcing patterns during the past 12-24 months, with companies engaging CDMOs earlier in the development cycle
Media

UK REACH reform falls short as industry warns of £500m+ compliance bill

The UK chemicals industry has condemned the Government's long-awaited response to the UK REACH Alternative Transitional Registration model consultation, arguing it does little to support growth or innovation
Manufacturing

Freudenberg Medical launches CleanAssure ISO Class 5 cleanroom service for sterile single-use biopharma assemblies

CleanAssure is an ISO Class 5 controlled cleanroom service delivering washed, dried and gamma-sterilised single-use assemblies to biopharmaceutical customers, addressing industry challenges around cleaning validation and contamination risk
Manufacturing

Mabwell signs Malaysia licensing deal for denosumab biosimilars MAILISHU and MAIWEIJIAN

Mabwell has entered a licensing and commercialisation agreement to bring its denosumab biosimilars to Malaysia, supporting regional access through local registration and supply of its Prolia and Xgeva reference products
Subscribe now